230 related articles for article (PubMed ID: 23409032)
21. Cushing's syndrome in an infant secondary to malignant adrenocortical tumors with somatic mutation of beta-catenin.
Pusantisampan T; Sangkhathat S; Kayasut K; Kanngurn S; Jaruratanasirikul S; Chotsampancharoen T; Kritsaneepaiboon S
Pediatr Dev Pathol; 2010; 13(3):238-42. PubMed ID: 19863445
[TBL] [Abstract][Full Text] [Related]
22. Wnt/beta-catenin pathway deregulation in childhood adrenocortical tumors.
Leal LF; Mermejo LM; Ramalho LZ; Martinelli CE; Yunes JA; Seidinger AL; Mastellaro MJ; Cardinalli IA; Brandalise SR; Moreira AC; Tone LG; Scrideli CA; Castro M; Antonini SR
J Clin Endocrinol Metab; 2011 Oct; 96(10):3106-14. PubMed ID: 21849527
[TBL] [Abstract][Full Text] [Related]
23. Subcellular localization of fibroblast growth factor receptor type 2 and correlation with CTNNB1 genotype in adrenocortical carcinoma.
Haase M; Thiel A; Scholl UI; Ashmawy H; Schott M; Ehlers M
BMC Res Notes; 2020 Jun; 13(1):282. PubMed ID: 32522271
[TBL] [Abstract][Full Text] [Related]
24. The effects of mitotane and 1α,25-dihydroxyvitamin D
Rubin B; Pilon C; Pezzani R; Rebellato A; Fallo F
J Endocrinol Invest; 2020 Mar; 43(3):357-367. PubMed ID: 31587178
[TBL] [Abstract][Full Text] [Related]
25. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
[TBL] [Abstract][Full Text] [Related]
26. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
Ragazzon B; Libé R; Gaujoux S; Assié G; Fratticci A; Launay P; Clauser E; Bertagna X; Tissier F; de Reyniès A; Bertherat J
Cancer Res; 2010 Nov; 70(21):8276-81. PubMed ID: 20959480
[TBL] [Abstract][Full Text] [Related]
27. [Effect of β-catenin gene silencing by shRNA on biologic characteristics of human esophageal carcinoma cells].
Wang JS; Ji AF; Wen JF; Ren HZ
Zhonghua Bing Li Xue Za Zhi; 2010 Dec; 39(12):835-41. PubMed ID: 21215100
[TBL] [Abstract][Full Text] [Related]
28. Inactivation of the Carney complex gene 1 (protein kinase A regulatory subunit 1A) inhibits SMAD3 expression and TGF beta-stimulated apoptosis in adrenocortical cells.
Ragazzon B; Cazabat L; Rizk-Rabin M; Assie G; Groussin L; Fierrard H; Perlemoine K; Martinez A; Bertherat J
Cancer Res; 2009 Sep; 69(18):7278-84. PubMed ID: 19738044
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive analysis of CTNNB1 in adrenocortical carcinomas: Identification of novel mutations and correlation to survival.
Maharjan R; Backman S; Åkerström T; Hellman P; Björklund P
Sci Rep; 2018 Jun; 8(1):8610. PubMed ID: 29872083
[TBL] [Abstract][Full Text] [Related]
30. Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo.
Ramachandran I; Thavathiru E; Ramalingam S; Natarajan G; Mills WK; Benbrook DM; Zuna R; Lightfoot S; Reis A; Anant S; Queimado L
Oncogene; 2012 May; 31(22):2725-37. PubMed ID: 22002305
[TBL] [Abstract][Full Text] [Related]
31. Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.
Xu Y; Dong B; Huang J; Kong W; Xue W; Zhu Y; Zhang J; Huang Y
Oncotarget; 2016 Jan; 7(3):3233-44. PubMed ID: 26673009
[TBL] [Abstract][Full Text] [Related]
32. Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors.
Bonnet S; Gaujoux S; Launay P; Baudry C; Chokri I; Ragazzon B; Libé R; René-Corail F; Audebourg A; Vacher-Lavenu MC; Groussin L; Bertagna X; Dousset B; Bertherat J; Tissier F
J Clin Endocrinol Metab; 2011 Feb; 96(2):E419-26. PubMed ID: 21084400
[TBL] [Abstract][Full Text] [Related]
33. A reappraisal of transcriptional regulation by NR5A1 and beta-catenin in adrenocortical carcinoma.
Lalli E
Front Endocrinol (Lausanne); 2023; 14():1303332. PubMed ID: 38155952
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.
Korah R; Healy JM; Kunstman JW; Fonseca AL; Ameri AH; Prasad ML; Carling T
Mol Cancer; 2013 Aug; 12():87. PubMed ID: 23915220
[TBL] [Abstract][Full Text] [Related]
35. A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas.
Hadjadj D; Kim SJ; Denecker T; Ben Driss L; Cadoret JC; Maric C; Baldacci G; Fauchereau F
Aging (Albany NY); 2017 Dec; 9(12):2695-2716. PubMed ID: 29283884
[TBL] [Abstract][Full Text] [Related]
36. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma.
Satoh K; Zhang L; Zhang Y; Chelluri R; Boufraqech M; Nilubol N; Patel D; Shen M; Kebebew E
Clin Cancer Res; 2016 Jul; 22(14):3458-66. PubMed ID: 26873959
[TBL] [Abstract][Full Text] [Related]
37. EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma.
Chen Q; Zheng PS; Yang WT
Oncotarget; 2016 Jun; 7(24):36115-36129. PubMed ID: 27092879
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of Aurora kinase A activity enhances the antitumor response of beta-catenin blockade in human adrenocortical cancer cells.
Maria AG; Silva Borges K; Lira RCP; Hassib Thomé C; Berthon A; Drougat L; Kiseljak-Vassiliades K; Wierman ME; Faucz FR; Faça VM; Tone LG; Stratakis CA
Mol Cell Endocrinol; 2021 May; 528():111243. PubMed ID: 33716050
[TBL] [Abstract][Full Text] [Related]
39. FSCN1 as a new druggable target in adrenocortical carcinoma.
Ruggiero C; Tamburello M; Rossini E; Zini S; Durand N; Cantini G; Cioppi F; Hantel C; Kiseljak-Vassiliades K; Wierman ME; Landwehr LS; Weigand I; Kurlbaum M; Zizioli D; Turtoi A; Yang S; Berruti A; Luconi M; Sigala S; Lalli E
Int J Cancer; 2023 Jul; 153(1):210-223. PubMed ID: 36971100
[TBL] [Abstract][Full Text] [Related]
40. Beta-catenin/Tcf-4 inhibition after progastrin targeting reduces growth and drives differentiation of intestinal tumors.
Pannequin J; Delaunay N; Buchert M; Surrel F; Bourgaux JF; Ryan J; Boireau S; Coelho J; Pélegrin A; Singh P; Shulkes A; Yim M; Baldwin GS; Pignodel C; Lambeau G; Jay P; Joubert D; Hollande F
Gastroenterology; 2007 Nov; 133(5):1554-68. PubMed ID: 17920061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]